These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study. Garcia-Pardo M; Ortega L; Fernández-Aceñero MJ; García Alfonso P; Martín M; Muñoz AJ J Gastrointest Cancer; 2021 Jun; 52(2):814-818. PubMed ID: 33683644 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic yield of extensive molecular profiling in cholangiocarcinoma: a retrospective single-center study. Vancanneyt J; Wilmsen B; Luyten C; Verslype C; Van Cutsem E; Roskams T; Tejpar S; Vanden Bempt I; Dekervel J J Cancer Res Clin Oncol; 2023 Sep; 149(11):9173-9181. PubMed ID: 37184679 [TBL] [Abstract][Full Text] [Related]
7. First proficiency testing for NGS-based and combined NGS- and FISH-based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma. Neumann O; Lehmann U; Bartels S; Pfarr N; Albrecht T; Ilm K; Christmann J; Volckmar AL; Goldschmid H; Kirchner M; Allgäuer M; Walker M; Kreipe H; Tannapfel A; Weichert W; Schirmacher P; Kazdal D; Stenzinger A J Pathol Clin Res; 2023 Mar; 9(2):100-107. PubMed ID: 36635225 [TBL] [Abstract][Full Text] [Related]
8. Role of molecular genetics in the clinical management of cholangiocarcinoma. Normanno N; Martinelli E; Melisi D; Pinto C; Rimassa L; Santini D; Scarpa A ESMO Open; 2022 Jun; 7(3):100505. PubMed ID: 35696744 [TBL] [Abstract][Full Text] [Related]
9. Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling. Silverman IM; Li M; Murugesan K; Krook MA; Javle MM; Kelley RK; Borad MJ; Roychowdhury S; Meng W; Yilmazel B; Milbury C; Shewale S; Feliz L; Burn TC; Albacker LA J Mol Diagn; 2022 Apr; 24(4):351-364. PubMed ID: 35176488 [TBL] [Abstract][Full Text] [Related]
10. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Ross JS; Wang K; Gay L; Al-Rohil R; Rand JV; Jones DM; Lee HJ; Sheehan CE; Otto GA; Palmer G; Yelensky R; Lipson D; Morosini D; Hawryluk M; Catenacci DV; Miller VA; Churi C; Ali S; Stephens PJ Oncologist; 2014 Mar; 19(3):235-42. PubMed ID: 24563076 [TBL] [Abstract][Full Text] [Related]
11. Molecular profiling and prognostic analysis in Chinese cholangiocarcinoma: an observational, retrospective single-center study. Zhang C; You X; Zhang Q; Wang D Invest New Drugs; 2024 Feb; 42(1):24-34. PubMed ID: 37975978 [TBL] [Abstract][Full Text] [Related]
12. Cholangiocarcinoma: Pathologic and Molecular Classification in the Era of Precision Medicine. Gopal P; Robert ME; Zhang X Arch Pathol Lab Med; 2024 Mar; 148(3):359-370. PubMed ID: 37327187 [TBL] [Abstract][Full Text] [Related]
13. ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer. Lee SH; Cheon J; Lee S; Kang B; Kim C; Shim HS; Park YN; Jung S; Choi SH; Choi HJ; Lee CK; Chon HJ Cancer Res Treat; 2023 Oct; 55(4):1291-1302. PubMed ID: 37139666 [TBL] [Abstract][Full Text] [Related]
14. Practical considerations for pathological diagnosis and molecular profiling of cholangiocarcinoma: an expert review for best practices. Evans M; Kendall T Expert Rev Mol Diagn; 2024 May; 24(5):393-408. PubMed ID: 38752560 [TBL] [Abstract][Full Text] [Related]
15. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. Churi CR; Shroff R; Wang Y; Rashid A; Kang HC; Weatherly J; Zuo M; Zinner R; Hong D; Meric-Bernstam F; Janku F; Crane CH; Mishra L; Vauthey JN; Wolff RA; Mills G; Javle M PLoS One; 2014; 9(12):e115383. PubMed ID: 25536104 [TBL] [Abstract][Full Text] [Related]
16. ERBB2 Pathway in Biliary Tract Carcinoma: Clinical Implications of a Targetable Pathway. Jacobi O; Ross JS; Goshen-Lago T; Haddad R; Moore A; Sulkes A; Brenner B; Ben-Aharon I Oncol Res Treat; 2021; 44(1-2):20-27. PubMed ID: 33279901 [TBL] [Abstract][Full Text] [Related]
17. ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma. Verdaguer H; Saurí T; Acosta DA; Guardiola M; Sierra A; Hernando J; Nuciforo P; Miquel JM; Molero C; Peiró S; Serra-Camprubí Q; Villacampa G; Aguilar S; Vivancos A; Tabernero J; Dienstmann R; Macarulla T Clin Cancer Res; 2022 Apr; 28(8):1662-1671. PubMed ID: 35042699 [TBL] [Abstract][Full Text] [Related]